Russian Lab Achieves ISO Accreditation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Russian Lab Achieves ISO Accreditation



The Rostov-on-Don Medicines Quality Control Laboratory of the Federal Service on Surveillance in Healthcare (Roszdravnadzor) has attained ISO/IEC 17025:2005 accreditation for testing and calibration laboratories. The facility is the first official medicines control laboratory in Russia to have achieved internationally recognized ISO accreditation, according to a press release from the U.S. Pharmacopeial (USP) Convention.

The accreditation was awarded by ACLASS, an accrediting body based in Washington, D.C., for seven key analytical tests: high-performance liquid chromatography, dissolution, ultra-violet visible spectroscopy, thin-layer chromatography, Karl Fischer titration, pH, and limulus amebocyte lysate.

The accreditation certifies that the Rostov-on-Don laboratory is providing valid and trustworthy data to Roszdravnadzor, the Russian drug-monitoring agency, helping to ensure the distribution of good quality medicines. The USP, provided technical assistance to Roszdravnadzor through its Promoting the Quality of Medicines (PQM) program. Assistance included conducting an assessment of the Rostov-on-Don laboratory’s quality management system against ISO/IEC standards; providing ongoing monitoring of the laboratory’s progress toward accreditation; and hosting Roszdravnadzor staff at its US headquarters to observe how USP’s quality management system complies with ISO standards. This support occurred in several stages between September 2011 and October 2012.

ISO/IEC 17025:2005 accreditation positions Rostov-on-Don as an international reference for labs working on quality control of pharmaceutical products. It extends the lab’s reach in supporting public health across Russia and the wider region.

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here